Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Li Auto Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Li Auto Inc trades at $11.3 (market cap $11.28B). The key difference: Li Auto Inc is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Li Auto Inc for 102 Days on average.
| KYMR | LI | |
|---|---|---|
Market Cap | $8.88B | $11.28B |
Volume | 1,028,790 | 2,730,590 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $22.72 |
52-Week Low | $55.80 | $10.69 |
Typical Hold Time | 0 Days | 102 Days |
Enterprise Value | $8.27B | $686.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Li Auto (LI) trades at $11.75, up 3.07% on the day but near 52-week lows amid declining delivery volumes and negative earnings surprises. The stock shows bearish technical signals with mixed fundamentals - revenue declined to $112.31B in 2025 while net income dropped to $1.12B. Recent September deliveries of 31,817 vehicles reflect near-term challenges despite new model launches including the Li i9 SUV and Li MEGA MPV.
Investment outlook remains cautious with analyst consensus at $15.18 target (29% upside) but execution risks high. Key opportunities include margin recovery potential and global expansion, while risks center on intense EV competition, cash burn, and Chinese market volatility. The stock appears undervalued on P/S (0.75x) but faces profitability challenges with negative ROE and net margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
